JP6975465B2 - 遺伝子改変細胞をポジティブに選択して、排除するための短ヘアピンｒｎａ（ｓｈｒｎａ７３４）およびその使用 - Google Patents

遺伝子改変細胞をポジティブに選択して、排除するための短ヘアピンｒｎａ（ｓｈｒｎａ７３４）およびその使用 Download PDF

Info

Publication number
JP6975465B2
JP6975465B2 JP2018543719A JP2018543719A JP6975465B2 JP 6975465 B2 JP6975465 B2 JP 6975465B2 JP 2018543719 A JP2018543719 A JP 2018543719A JP 2018543719 A JP2018543719 A JP 2018543719A JP 6975465 B2 JP6975465 B2 JP 6975465B2
Authority
JP
Japan
Prior art keywords
cells
gene
cell
genetically modified
polynucleotide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018543719A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509034A5 (https=
JP2019509034A (ja
Inventor
スン アン，ドン
シミズ，サキ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California San Diego UCSD
Original Assignee
University of California
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California San Diego UCSD filed Critical University of California
Publication of JP2019509034A publication Critical patent/JP2019509034A/ja
Publication of JP2019509034A5 publication Critical patent/JP2019509034A5/ja
Priority to JP2021177252A priority Critical patent/JP7350361B2/ja
Application granted granted Critical
Publication of JP6975465B2 publication Critical patent/JP6975465B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02008—Hypoxanthine phosphoribosyltransferase (2.4.2.8)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018543719A 2016-02-19 2017-02-17 遺伝子改変細胞をポジティブに選択して、排除するための短ヘアピンｒｎａ（ｓｈｒｎａ７３４）およびその使用 Active JP6975465B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021177252A JP7350361B2 (ja) 2016-02-19 2021-10-29 遺伝子改変細胞をポジティブに選択して、排除するための短ヘアピンｒｎａ（ｓｈｒｎａ７３４）およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662297432P 2016-02-19 2016-02-19
US62/297,432 2016-02-19
PCT/US2017/018483 WO2017143266A1 (en) 2016-02-19 2017-02-17 Short hairpin rna (shrna734) and use of same to positively select and eliminate genetically modified cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021177252A Division JP7350361B2 (ja) 2016-02-19 2021-10-29 遺伝子改変細胞をポジティブに選択して、排除するための短ヘアピンｒｎａ（ｓｈｒｎａ７３４）およびその使用

Publications (3)

Publication Number Publication Date
JP2019509034A JP2019509034A (ja) 2019-04-04
JP2019509034A5 JP2019509034A5 (https=) 2020-03-19
JP6975465B2 true JP6975465B2 (ja) 2021-12-08

Family

ID=59625420

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018543719A Active JP6975465B2 (ja) 2016-02-19 2017-02-17 遺伝子改変細胞をポジティブに選択して、排除するための短ヘアピンｒｎａ（ｓｈｒｎａ７３４）およびその使用
JP2021177252A Active JP7350361B2 (ja) 2016-02-19 2021-10-29 遺伝子改変細胞をポジティブに選択して、排除するための短ヘアピンｒｎａ（ｓｈｒｎａ７３４）およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021177252A Active JP7350361B2 (ja) 2016-02-19 2021-10-29 遺伝子改変細胞をポジティブに選択して、排除するための短ヘアピンｒｎａ（ｓｈｒｎａ７３４）およびその使用

Country Status (8)

Country Link
US (2) US11377659B2 (https=)
EP (1) EP3416660A4 (https=)
JP (2) JP6975465B2 (https=)
KR (1) KR20180114008A (https=)
CN (1) CN108495640B (https=)
AU (1) AU2017221456B2 (https=)
HK (1) HK1257668A1 (https=)
WO (1) WO2017143266A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7410856B2 (ja) 2017-07-18 2024-01-10 シーエスエル・ベーリング・ジーン・セラピー・インコーポレイテッド ドナー改変細胞の選択のための調節可能スイッチ
CN111164211B (zh) * 2017-07-18 2024-08-02 杰特贝林基因治疗股份有限公司 用于治疗β-血红蛋白病的组合物和方法
KR20210118833A (ko) * 2018-12-23 2021-10-01 씨에스엘 베링 엘엘씨 킬 스위치를 갖는 공여 t 세포
EP3897745A1 (en) * 2018-12-23 2021-10-27 CSL Behring LLC Haematopoietic stem cell-gene therapy for wiskott-aldrich syndrome

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997043900A1 (en) 1996-05-24 1997-11-27 The President And Fellows Of Harvard College In vivo selection
AU7605796A (en) 1996-11-04 1998-05-29 Saint Jude Children's Research Hospital (in vivo) selection of primitive hematopoietic cells
US20030032003A1 (en) 2000-02-02 2003-02-13 Schiestl Robert H. In vivo selection
WO2002040049A2 (en) 2000-11-14 2002-05-23 The General Hospital Corporation Blockade of t cell migration into epithelial gvhd target tissues
US7737124B2 (en) * 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
WO2005056761A2 (en) * 2003-12-05 2005-06-23 Massachusetts Institute Of Technology REAGENTS AND METHODS FOR IDENTIFICATION OF RNAi PATHWAY GENES AND CHEMICAL MODULATORS OF RNAi
EP1607482A1 (de) * 2004-06-16 2005-12-21 Gbf-Gesellschaft Für Biotechnologische Forschung Mbh RNAi-basierte Verfahren zur Selektion von transfizierten eukaryontischen Zellen
WO2008076370A2 (en) * 2006-12-18 2008-06-26 The General Hospital Corporation P21 compositions and methods for the treatment of hiv
WO2012061075A2 (en) 2010-10-25 2012-05-10 The Regents Of The University Of California Hiv resistant and functional hematopoietic stem/progenitor cells and macrophages from induced pluripotent stem cells
GB201301125D0 (en) * 2013-01-22 2013-03-06 Horizon Discovery Ltd Methods for improving the efficency of gene targeting
EP3027755B1 (en) * 2013-08-02 2019-10-09 The Regents of The University of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
WO2017079400A1 (en) * 2015-11-04 2017-05-11 The Trustees Of The University Of Pennsylvania Methods and compositions for gene editing in hematopoietic stem cells
CN111164211B (zh) * 2017-07-18 2024-08-02 杰特贝林基因治疗股份有限公司 用于治疗β-血红蛋白病的组合物和方法

Also Published As

Publication number Publication date
AU2017221456B2 (en) 2024-04-04
CN108495640A (zh) 2018-09-04
EP3416660A4 (en) 2019-11-06
EP3416660A1 (en) 2018-12-26
WO2017143266A1 (en) 2017-08-24
JP7350361B2 (ja) 2023-09-26
JP2019509034A (ja) 2019-04-04
CA3012332A1 (en) 2017-08-24
US20230076635A1 (en) 2023-03-09
HK1257668A1 (zh) 2019-10-25
CN108495640B (zh) 2022-11-04
KR20180114008A (ko) 2018-10-17
US20210310007A1 (en) 2021-10-07
JP2022033729A (ja) 2022-03-02
AU2017221456A1 (en) 2018-07-19
US11377659B2 (en) 2022-07-05

Similar Documents

Publication Publication Date Title
US11857574B2 (en) Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence
JP7350361B2 (ja) 遺伝子改変細胞をポジティブに選択して、排除するための短ヘアピンｒｎａ（ｓｈｒｎａ７３４）およびその使用
US20190255107A1 (en) Modulation of novel immune checkpoint targets
WO2018067991A1 (en) Modulation of novel immune checkpoint targets
BR112019019426A2 (pt) Biomarcadores e terapias com células t car com eficácia intensificada
JP2021505200A (ja) ゲノムインプリンティングの障害を治療するための組成物及び方法
JP2024175115A (ja) Ｃｄ４欠損ｃａｒ ｔ細胞および抗ｃｄ４ ｃａｒ ｔ細胞を作製するための方法および組成物ならびにその使用
JP2017506232A (ja) 腫瘍を治療するための阻害性オリゴヌクレオチド
AU2021256428A1 (en) Integration of large adenovirus payloads
US20260108604A1 (en) Car t cell compositions for treatment of cancer
TWI670064B (zh) 抗病毒劑及治療病毒感染之方法
CA3012332C (en) Short hairpin rna (shrna734) and use of same to positively select and eliminate genetically modified cells
US12194057B2 (en) NXTAR-derived oligonucleotides and uses thereof
US20240050435A1 (en) Methods for treating cancer
CN119968464A (zh) 具有组合基因扰动的免疫细胞

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210922

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211029

R150 Certificate of patent or registration of utility model

Ref document number: 6975465

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250